arrow
M

Michael D. Oberst

AstraZeneca
H指数:33
被引数:3,605

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2021-07-0651
OA
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
MABS
IF7.3
2021-01-0413
OAAI
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
2019-08-2224
OAAI
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
2018-04-3036
OAAI
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2017-07-0243
OAAI
MEDI1873, a GITR ligand fusion protein (GITRL FP), induces effector T-cell proliferation, modulates T-regulatory cell function and has the potential to combine with checkpoint inhibitors
2017-07-010
PRE
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
2017-02-0336
OAAI